hotspot -WSS

hotspot

author：fashion 2025-10-02 14:39:10 - browse：8

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Ebola public health emergency is over, WHO declares

knowledge

WSS

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

A new nitrogen execution bill also undermines medical licensing

States increasingly look to regulate hospital facility fees

R1 RCM gets $5.8 billion buyout offer from private equity firm

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Stanford president to resign after investigation of research

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Alabama hospital puts IVF treatments on hold

Wildfire smoke exposes gaps in outdoor worker protections

Stanford president to resign after investigation of research

United colonoscopy coverage change 'may cost lives,' doctors say

New documents shed light on MD Anderson Cancer Institute feud

Sports medicine is finally prioritizing gender equality

Alabama frozen embryo ruling has major implications for IVF clinics

BioMarin wins approval for gene therapy to treat hemophilia A

Lindsay Lohan welcomes 1st child with husband Bader Shammas

hotspot

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Researchers separate signal from noise in heart wearable data

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

He's a Nobel laureate. Critics say he was misleading on Covid

Alabama IVF ruling threatens families facing fatal genetic disease

Stanford president to resign after investigation of research

focus

Wikipedia

knowledge

entertainment